Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Chamberlin

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
The New England Journal of Medicine|June 29, 2022
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) InfectionJulie Boucau, Caitlin Marino, James Regan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Duration of viable virus shedding in SARS-CoV-2 omicron variant infectionJulie Boucau, Caitlin Marino, James Regan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody ResponsesMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
JCI Insight|October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variantMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
The New England Journal of Medicine|June 29, 2022
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) InfectionJulie Boucau, Caitlin Marino, James Regan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Duration of viable virus shedding in SARS-CoV-2 omicron variant infectionJulie Boucau, Caitlin Marino, James Regan, et al.
Medrxiv : the Preprint Server for Health Sciences|March 9, 2022
Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody ResponsesMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
JCI Insight|October 10, 2022
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variantMichael S Seaman, Mark J Siedner, Julie Boucau, et al.
Pageof 5